MyStart Health Review: Pricing, Plans, and Real Results

MyStart Health provides compounded semaglutide and compounded tirzepatide through a standard telehealth model. The intake process evaluates eligibility - BMI, weight history, current medications, and contraindications - and a licensed provider issues a prescription for qualifying patients. Medication ships from a licensed 503B compounding facility.

The titration protocol follows established clinical guidelines: semaglutide starting at 0.25mg weekly for four weeks, then stepping up through 0.5mg, 1mg, 1.7mg, and 2.4mg maintenance doses at 4-8 week intervals based on tolerance. The escalation is designed to minimize GI side effects by allowing the body to adapt at each dose level before increasing.

Monthly check-ins with a licensed provider are included in the subscription. For first-time GLP-1 users, these check-ins serve an educational function beyond clinical monitoring - they are opportunities to ask questions about what you are experiencing, confirm that side effects are within the expected range, and receive guidance on dietary adjustments that improve tolerability and outcomes.

Nutritional guidance resources are included, with particular attention to the adjustments that help new GLP-1 users navigate the first weeks of treatment: protein intake recommendations, meal timing strategies that minimize nausea, hydration guidance, and what to expect as appetite changes.

MyStart Health's orientation toward first-time GLP-1 users shapes several aspects of the platform beyond just the name.

The intake process explains what compounded semaglutide is and how it differs from branded Wegovy - information that experienced GLP-1 users already know but that first-time users often need before they are comfortable starting. The FAQ resources on the platform address the questions that new users consistently ask: Does the injection hurt? What do I do if I feel nauseous? What happens if I miss a dose? How do I store the medication?

The provider check-in structure accommodates the learning curve of new users. A first-time GLP-1 user at month one has different clinical needs than a patient who has been on semaglutide for 18 months. The check-in at week 4-6 for a new user is often spent largely on education - confirming the injection technique is correct, explaining that the mild nausea they are experiencing is expected and typically resolves, and setting expectations for when meaningful weight loss should begin appearing.

The between-check-in messaging support is particularly valuable for first-time users because questions arise between scheduled appointments. The ability to message a provider when nausea appears worse than expected, when an injection site reaction develops, or when the medication seems to be causing constipation - rather than waiting two to four weeks for a scheduled check-in - prevents the anxiety and premature discontinuation that often derails first-time GLP-1 users.

MyStart Health offers both GLP-1 medications and the clinical rationale for choosing between them. Compounded semaglutide (same active ingredient as Wegovy and Ozempic) is typically the recommended starting point for first-time GLP-1 users. The longer real-world safety record, the more developed patient support literature, and the lower cost make it the appropriate first choice for someone who has never used a GLP-1 medication. Clinical trial data from the STEP program showed 14.9% average weight loss over 68 weeks at the 2.4mg maintenance dose. Compounded tirzepatide (same active ingredient as Zepbound and Mounjaro) activates both GLP-1 and GIP receptors, producing stronger average weight loss - 20.9% over 72 weeks in the SURMOUNT-1 trial. MyStart offers tirzepatide as a first-line option for patients who specifically request it or who have specific metabolic profiles where the dual-agonist mechanism offers advantages. The medication format from MyStart's 503B pharmacy partners is typically pre-filled injection pens or autoinjectors, which simplify the self-administration process for first-time users considerably. The visual and tactile similarity to an insulin pen or EpiPen - pre-loaded, auto-injecting, with a short needle - makes the physical act of injecting much less intimidating than a traditional syringe and vial. Injection training materials included with the first shipment cover technique, injection site rotation (abdomen, thigh, upper arm), storage requirements (refrigeration at 36-46F), and what to do if a dose is missed.

The first four weeks of GLP-1 treatment are the most critical for long-term adherence. This is when side effects are most pronounced, when expectations need calibration, and when habits that support the medication's mechanism need to be established. MyStart's first-time-user orientation focuses clinical attention precisely in this window. The most common first-month experience: mild nausea beginning 6-12 hours after the first injection, typically lasting 24-48 hours before resolving. Appetite reduction that feels subtle at the introductory dose but becomes more pronounced by week 3-4. Constipation that creeps up without warning. Fatigue in the first week that resolves as the body adapts. MyStart provides specific guidance for each of these common experiences. For nausea: inject at bedtime so you sleep through the peak nausea window; eat small high-protein meals; avoid high-fat foods for 24 hours after injection. For constipation: increase dietary fiber, increase water intake, and consider a fiber supplement if needed. For the subtle effect at the introductory dose: this is expected - the dose escalation schedule is what brings the meaningful appetite suppression. The first-month check-in at MyStart is specifically structured to address these early experiences. The provider confirms tolerability, answers questions about what is normal, and sets expectations for the dose escalation that will bring more meaningful appetite suppression. For first-time users who may have expected more dramatic early results, this context is clinically and psychologically important for maintaining treatment commitment through the early weeks.

MyStart Health's pricing is positioned at the accessible end of the compounded GLP-1 market, consistent with the first-timer-friendly brand positioning. Compounded semaglutide starts at approximately $149 per month at the introductory 0.25mg dose. As doses increase through the titration schedule, pricing adjusts - typically $179-199 per month at mid-range doses and $199-229 per month at maintenance doses. Tirzepatide is priced approximately $199-249 per month.

The monthly fee covers medication, shipping, the provider check-in, and access to the nutritional guidance and educational resources. No separate consultation fees are charged for the check-ins, and the messaging support between appointments is included.

For first-time users who are uncertain whether GLP-1 treatment is right for them, MyStart's pricing allows a meaningful evaluation period without a prohibitive financial commitment. At $149 for the first month, you can experience the medication at the introductory dose, complete the first provider check-in, and have a clinical conversation about whether to continue before committing to higher doses and potentially higher monthly costs.

The platform is cash-pay - no insurance billing. HSA and FSA cards are accepted. For patients who have potential insurance coverage for branded GLP-1 medications through their employer plan, a platform that helps navigate prior authorization may save money. For patients without such coverage, MyStart's pricing is competitive.

Months 1-3: Weight loss is typically modest - 3-8 pounds is common. The dose is low (0.25-0.5mg) and the appetite reduction effect is not yet at maximum. Months 4-6: As dosing reaches 1-1.7mg, weight loss accelerates. Most patients in clinical trials lost the majority of their total weight loss during this phase.

At 3 months: Most patients are in the mid-titration phase, at 0.5-1mg semaglutide. Appetite suppression is noticeable but not yet at maximum. Weight loss of 5-10 pounds is typical. GI side effects from the first weeks have typically resolved. Energy and well-being are often improved as dietary patterns have adjusted. This is the point where the investment in the process begins to show tangible returns.

At 6 months: Patients reaching therapeutic doses (1-2.4mg) are experiencing meaningful appetite suppression. Average weight loss in clinical trials at this point is in the 8-12% range. Food noise - the persistent preoccupation with food and eating that drives overconsumption - is substantially reduced at therapeutic doses. This is often when patients report the most qualitative improvement in their relationship with food.

At 12 months: The STEP trial data shows an average of 14.9% weight loss at 68 weeks on semaglutide. Individual results range widely - some patients lose 5%, some lose 25% or more. The response is determined by individual pharmacogenomics, dose reached, dietary patterns, and activity level alongside the medication. Patients who have not reached their target by month 12 should discuss whether tirzepatide or dose optimization might improve results.

MyStart's monthly check-in structure provides clinical accountability at each phase. The provider monitoring your progress at month 3 knows your month 1 baseline and can assess whether your trajectory is on track for good outcomes.

MyStart Health competes with Shed, Skinny.Rx, Sprout Health, iVIM Health, Eden, and dozens of other compounded GLP-1 platforms that have entered the market as demand for semaglutide access has grown. The differentiation at the pricing and feature level among these platforms is modest - all offer compounded semaglutide and tirzepatide, monthly check-ins, and nutritional guidance at similar price points.

The meaningful differentiator for MyStart is the explicit orientation toward first-time users. The educational resources, the structured first-month onboarding, and the communication style are calibrated for someone new to GLP-1 treatment rather than someone transferring from another platform. For experienced GLP-1 users who have already been through the learning curve, this orientation is less relevant - they want medication access and dose management, not educational onboarding.

For patients who are genuinely starting GLP-1 treatment for the first time and want a platform that meets them with appropriate context and support, MyStart's positioning is genuinely useful. For patients who already know exactly how semaglutide works and want the lowest-cost access, a more purely price-competitive platform may serve them better.

The brand clarity of MyStart - it knows who it is for and communicates consistently to that audience - is a feature in a market where many platforms try to be all things to all patients.